GoAI
Get started
Miricor Enterprises Holdings Ltd logo

Miricor Enterprises Holdings Ltd

1827.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$0.77

−HK$0.03 · -3.75%

Aug 21, 6:07 PM HKT

1827.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Miricor Enterprises Holdings Limited, an investment holding company, provides non-surgical medical aesthetic, wellness beauty services, and skincare products in Hong Kong and Mainland China. It offers non-surgical medical aesthetic services, including injection procedures; and treatment services, as well as prescription and dispensing medical products. The company also sells skin care products, such as cleansers, toners, serums, moisturizers, eye care products, ultraviolet protection products, and masks. In addition, it engages in the wholesale of skincare products; owns trademarks; and offers management services. Further, the company operates medical aesthetic centers under the CosMax+, XOVE, and VITAE brand names. Miricor Enterprises Holdings Limited was founded in 2009 and is headquartered in Central, Hong Kong.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
HK
CEO
Ka Yee Lai
Listed since
Jan 11, 2017
Employees
235

Market position

Day range

Current HK$0.77

52-week range

Current HK$0.77

Open
HK$0.77
Previous close
HK$0.80
Volume
15K
1.13× average
Average volume
13.33K
Average daily volume
Market cap
308M HKD
Beta
0.01
Market reference 1
50-day average
HK$0.7985
-3.57% below average
200-day average
HK$0.8604
-10.50% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
236.46M HKD
P/E (TTM)
10.77×
P/B (TTM)
1.95×
P/S (TTM)
0.46×
EV / EBITDA
2.8×
Earnings yield
2.99%
Free cash flow yield
18.12%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
44.68%
Operating margin
17.16%
Net margin
4.24%
Return on equity
7.10%
Return on assets
2.65%
Return on invested capital
4.99%

Financial health

Debt / equity
0.32×
Current ratio
1.35×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends64%39%14%-12%Gross margin, FY2021: 57.58%Gross margin, FY2022: 51.44%Gross margin, FY2023: 45.60%Gross margin, FY2024: 52.37%Gross margin, FY2025: 42.84%Operating margin, FY2021: 8.62%Operating margin, FY2022: -5.39%Operating margin, FY2023: -1.75%Operating margin, FY2024: 5.44%Operating margin, FY2025: 3.94%Net margin, FY2021: 6.97%Net margin, FY2022: -4.43%Net margin, FY2023: -2.55%Net margin, FY2024: 2.63%Net margin, FY2025: 3.10%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 57.58%. Gross margin FY2022 51.44%. Gross margin FY2023 45.60%. Gross margin FY2024 52.37%. Gross margin FY2025 42.84%. Operating margin FY2021 8.62%. Operating margin FY2022 -5.39%. Operating margin FY2023 -1.75%. Operating margin FY2024 5.44%. Operating margin FY2025 3.94%. Net margin FY2021 6.97%. Net margin FY2022 -4.43%. Net margin FY2023 -2.55%. Net margin FY2024 2.63%. Net margin FY2025 3.10%.

Income trends

Revenue

362.39M HKD-10.11%

Operating income

14.27M HKD-34.92%

Net income

11.23M HKD+6.07%
Income trends across reported periods546.18M HKD338.49M HKD130.8M HKD−76.88M HKDRevenue, FY2021: 363.92M HKDRevenue, FY2022: 463.12M HKDRevenue, FY2023: 494.26M HKDRevenue, FY2024: 403.15M HKDRevenue, FY2025: 362.39M HKDOperating income, FY2021: 31.38M HKDOperating income, FY2022: −24.96M HKDOperating income, FY2023: −8.65M HKDOperating income, FY2024: 21.92M HKDOperating income, FY2025: 14.27M HKDNet income, FY2021: 25.38M HKDNet income, FY2022: −20.5M HKDNet income, FY2023: −12.62M HKDNet income, FY2024: 10.59M HKDNet income, FY2025: 11.23M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 363.92M HKD. Revenue FY2022 463.12M HKD. Revenue FY2023 494.26M HKD. Revenue FY2024 403.15M HKD. Revenue FY2025 362.39M HKD. Operating income FY2021 31.38M HKD. Operating income FY2022 −24.96M HKD. Operating income FY2023 −8.65M HKD. Operating income FY2024 21.92M HKD. Operating income FY2025 14.27M HKD. Net income FY2021 25.38M HKD. Net income FY2022 −20.5M HKD. Net income FY2023 −12.62M HKD. Net income FY2024 10.59M HKD. Net income FY2025 11.23M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue362.39M HKD403.15M HKD494.26M HKD463.12M HKD363.92M HKD
Cost of goods sold207.14M HKD192.02M HKD268.89M HKD224.89M HKD154.38M HKD
Gross profit155.25M HKD211.14M HKD225.37M HKD238.23M HKD209.54M HKD
Selling, general, and administrative140.98M HKD49.98M HKD90.95M HKD88.9M HKD65.56M HKD
Operating expenses140.98M HKD189.21M HKD234.02M HKD228.66M HKD175.94M HKD
Interest income6.2M HKD6.11M HKD5.32M HKD2.35M HKD494K HKD
Interest expense4.09M HKD5.35M HKD5.16M HKD3.66M HKD3.03M HKD
Depreciation and amortization65.85M HKD77.98M HKD93.24M HKD90.55M HKD59.79M HKD
Operating income14.27M HKD21.92M HKD−8.65M HKD−24.96M HKD31.38M HKD
Net income11.23M HKD10.59M HKD−12.62M HKD−20.5M HKD25.38M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.040.01-0.03-0.07Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q2 '24Q3 '24Q4 '24
Q4 2022, reported Nov 26, 2022: actual 0.004, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 31, 2023: actual -0.03, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 27, 2023: actual -0.03, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 30, 2023: actual -0.016, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 25, 2023: actual -0.016, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 25, 2024: actual 0.001, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Sep 13, 2024: actual -0.001, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 29, 2024: actual -0.001, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates133.77M120.81M107.85M94.89MQ4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q2 '24Q3 '24Q4 '24
Q4 2022, reported Nov 26, 2022: actual 105.95M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 31, 2023: actual 125.61M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 27, 2023: actual 125.61M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 30, 2023: actual 118.51M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 25, 2023: actual 118.51M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 25, 2024: actual 128.63M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Sep 13, 2024: actual 100.04M HKD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 29, 2024: actual 100.04M HKD, estimate —, surprise —, Comparison unavailable.

1827.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

Continue in GoAI

Research 1827.HK

research.disclaimer